Marc Martinell

Marc obtained a PhD in Chemistry from the University of Barcelona. He has broad experience in drug discovery and biotechnology through his participation at companies such as Crystax Pharmaceuticals and Oryzon Genomics where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry and hit ID through a fragment-based approach. At Oryzon, Marc actively contributed to the identification of the first-in-class inhibitors for the epigenetic target LSD1 currently in clinical studies and licensed to Roche. In 2011 Marc co-founded Minoryx Therapeutics, a clinical stage biotech company focused on the development of new drugs for a group of rare diseases known as Inborn Errors of Metabolism. Marc is co-author of several patents and publications.